Search the Newsreel

Traws Pharma shares rise after Q2 loss comes in better than expected

Medical research: syringe, bottles and mask ©Bicanski Traws Pharma Inc. (NASDAQ:TRAW) shares gained 3.9% in pre-market trading on Monday after the clinical-stage biopharmaceutical company reported a second-quarter loss that was narrower than Wall Street had anticipated. For the quarter ended June 30, 2026, Traws …

Neo Performance Materials: The Scarcity Premium Is Becoming An Operating Business

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given "Buy" Rating at Chardan Capital

Russian Strike Hits ArcelorMittal Ukraine Plant, Disrupts Steel Output

A Russian missile strike on ArcelorMittal Kryvyi Rih, a major Ukrainian industrial facility and part of the world's second-largest steelmaker, killed two people and injured over a dozen workers. The attack damaged energy supply and blast furnace operations, forcing a temporary halt in steel …

Form 8K Dermata Therapeutics Inc For: 17 August By Investing.com

The article reports that Dermata Therapeutics Inc. filed a Form 8K on August 17th. This filing is a significant event for investors as it typically discloses important unscheduled material events or corporate changes that shareholders should be aware of. The article provides only this …

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $30.00

Mizuho has raised its price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) to $30.00 from $24.00, maintaining an "outperform" rating, indicating a potential 38.7% upside. Despite this, the company reported a quarterly loss of $0.39 per share, missing analyst estimates. Institutional investors and hedge funds hold …

EYPT Looks 4000.0% Overvalued on GF Value™

EyePoint Pharmaceuticals (EYPT) is considered 4000.0% overvalued based on GuruFocus's GF Value™ metric, trading at $14.76 against an estimated fair value of $0.36. This extreme valuation comes despite its Duravyu wet AMD trial showing mixed results—failing the primary endpoint in the overall dataset but …

What Could Meta Platforms (META) Off Balance Sheet AI Financing Mean For Investors?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Meta Platforms (NasdaqGS:META) is expanding the use of off-balance-sheet credit backstops to finance AI …

Meta trial: States allege Facebook, Instagram addicted kids

Meta Platforms went to trial Tuesday in federal court in Oakland, California, facing accusations from state attorneys general that the company deliberately designed Facebook and Instagram to hook children, misled the public about the risks, and collected data on minors in violation of federal …

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Rhythm Pharmaceuticals, Inc. BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher "AJ" Joshi, M.D., as Chief Medical …

Meta social media addiction trial, earnings from Walmart & Target: What to watch on Monday

Asking for a Trend Host, Josh Lipton breaks down what investors should be on the lookout for the week of Monday, August 17, including opening arguments in the Meta (META) social media addiction trial, earnings from Walmart (WMT), Target (TGT), Lowe's (LOW), and Home …

Sprouts to anchor Grand Imperial Marketplace center and 5 more businesses announced

A new Sprouts Farmers Market will anchor the Grand Imperial Marketplace in Spring, Texas, a 170,000-square-foot retail development. Alongside Sprouts, Marshalls, Ross, Burlington, Five Below, and Planet Fitness are also confirmed. Construction for the Sprouts location is set to begin this fall, with completion …

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00

HC Wainwright has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $47.00 from $44.00, maintaining a "buy" rating and implying a 59% upside. This comes amidst a generally positive analyst sentiment, with eight analysts rating the stock a "Buy," one a "Hold," and …

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to diagnose recurrent brain metastases and showed …

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics is scheduled to meet with the U.S. FDA on October 1st, 2026, for an End-of-Phase 2 meeting to discuss the pivotal Phase 3 trial design for RAD101. This imaging agent, which targets fatty acid synthase (FASN), is being developed for the diagnosis …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand

NRX Pharmaceuticals reported a net loss of $18.0 million for the first half of 2026, with an operating loss widening to $11.3 million. The company holds $26.7 million in cash and expects current resources, revenue growth, and an at-the-market facility to fund operations for …

Hyphens Pharma Lifts Margins and Profit as Portfolio Revamp Takes Hold

Neuberger Berman Next Generation Connectivity Fund Inc.'s Dividend Analysis

Kelun-Biotech Announces 2026 Interim Results

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: Revenue amounted to approximately RMB …

Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and …

Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally …

UBS raises Acadia Pharmaceuticals stock price target on trial optimism

UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its …

Mizuho raises Amylyx stock price target to $30 on higher pricing

Mizuho has increased its price target for Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) shares to $30 from $24, while maintaining an Outperform rating, due to updated pricing assumptions for its lead asset, avexitide. The firm anticipates positive Phase 3 LUCIDITY study data for avexitide in late …

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter

NRx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting significant progress in advancing its preservative-free ketamine ANDA towards FDA approval and commercialization. The company secured $22.3 million in gross proceeds from a public offering, ensuring over a year of operations, and expanded its clinical …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

Two Squeezed Hyperscalers: Does Meta or Amazon Have The Bigger Cash Flow Problem?

Quick Read AMZN burned -$8.8B in free cash flow last quarter, but META's slim $784M surplus masks deeper structural risk with no cloud revenue to recoup hardware costs. AWS hit a 39% margin with a $496B backlog, giving Amazon a metered cash recovery loop …

Weekly Recap: 191 MW Rockdale supply deal and pivot to AI data centers

Riot Platforms (RIOT) is transitioning its business focus from Bitcoin mining to AI data centers, securing a 20-year, 191 MW deal with Anthropic for its Rockdale facility. This strategic shift comes amid falling miner revenues and rising power costs, with the company reporting strong …

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Which part of the Poolbeg Pharma (LSE:POLB) immunotherapy story is driving UK small-cap interest today?

Google, Amazon, and Meta All Just Raised Capex Guidance Again. This Boring Industrial Wins No Matter Whose AI Infrastructure Is Best.

If there was any worry that spending on artificial intelligence (AI) was finally set to slow down, it's just been wiped away. Not only are big tech companies not dialing back their aggressive investments in AI infrastructure, but they're ramping them up. Google parent …

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Veradermics, Inc SEC Filing (Aug 17, 2026)

Veradermics, Inc. (NYSE: MANE) had an EFFECT filing accepted by the SEC EDGAR on August 17, 2026, with an effectiveness date of August 14, 2026, at 4:00 P.M. The filing was Form S-1. The company's recent news includes financial results, clinical progress updates, and …

Traws Pharma beats Q2 loss estimates, shares jump 4%

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus …